# Adderall XR and Processing Speed in Multiple Sclerosis (MS)

> **NCT01667484** · PHASE2,PHASE3 · COMPLETED · sponsor: **London Health Sciences Centre** · enrollment: 70 (actual)

## Conditions studied

- Impaired Processing Speed
- Cognitive Impairment
- Multiple Sclerosis

## Interventions

- **DRUG:** Adderall XR 5mg
- **DRUG:** Adderall XR 10 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01667484
- **Lead sponsor:** London Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-02
- **Final completion:** 2015-02
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2015-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01667484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01667484, "Adderall XR and Processing Speed in Multiple Sclerosis (MS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01667484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*